Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-23-007172
Filing Date
2023-04-28
Accepted
2023-04-28 09:00:18
Documents
6
Period of Report
2023-06-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A tmb-20230615xdef14a.htm DEF 14A 690796
2 GRAPHIC tmb-20230615xdef14a_a001.jpg GRAPHIC 10189
3 GRAPHIC tmb-20230615xdef14a_a012.jpg GRAPHIC 41473
4 GRAPHIC tmb-20230615xdef14a_a013.jpg GRAPHIC 41332
5 GRAPHIC tmb-20230615xdef14a_bg001.jpg GRAPHIC 183165
6 GRAPHIC tmb-20230615xdef14a_bg002.jpg GRAPHIC 154198
  Complete submission text file 0001558370-23-007172.txt   1285216
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37719 | Film No.: 23860671
SIC: 2834 Pharmaceutical Preparations